Operating Income (Loss) in USD of REGENEREX PHARMA, INC. from Q3 2010 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
REGENEREX PHARMA, INC. quarterly/annual Operating Income (Loss) history and change rate from Q3 2010 to Q3 2025.
  • REGENEREX PHARMA, INC. Operating Income (Loss) for the quarter ending 30 Sep 2025 was -$787K, a 204% decline year-over-year.
  • REGENEREX PHARMA, INC. Operating Income (Loss) for the twelve months ending 30 Sep 2025 was -$2.73M, a 165% decline year-over-year.
  • REGENEREX PHARMA, INC. annual Operating Income (Loss) for 2024 was -$1.83M, a 47.3% increase from 2023.
  • REGENEREX PHARMA, INC. annual Operating Income (Loss) for 2023 was -$3.47M, a 3504% decline from 2022.
  • REGENEREX PHARMA, INC. annual Operating Income (Loss) for 2022 was -$96.2K, a 23.8% increase from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Change (%)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Change (%)

REGENEREX PHARMA, INC. Quarterly Operating Income (Loss) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$2.73M -$787K -$528K -204% 01 Jul 2025 30 Sep 2025 10-Q 17 Nov 2025
Q2 2025 -$2.21M -$634K -$380K -149% 01 Apr 2025 30 Jun 2025 10-Q 14 Aug 2025
Q1 2025 -$1.83M -$1M -$722K -257% 01 Jan 2025 31 Mar 2025 10-K 30 Jun 2025
Q4 2024 -$1.1M -$312K -$72.1K -30.1% 01 Oct 2024 31 Dec 2024 10-Q 07 Feb 2025
Q3 2024 -$1.03M -$258K +$2.53M +90.7% 01 Jul 2024 30 Sep 2024 10-Q 17 Nov 2025
Q2 2024 -$3.56M -$254K -$94.1K -58.8% 01 Apr 2024 30 Jun 2024 10-Q 14 Aug 2025
Q1 2024 -$3.47M -$280K -$252K -891% 01 Jan 2024 31 Mar 2024 10-K 30 Jun 2025
Q4 2023 -$3.21M -$239K -$210K -723% 01 Oct 2023 31 Dec 2023 10-Q 07 Feb 2025
Q3 2023 -$3M -$2.79M -$2.76M -12855% 01 Jul 2023 30 Sep 2023 10-Q 04 Nov 2024
Q2 2023 -$239K -$160K -$143K -827% 01 Apr 2023 30 Jun 2023 10-Q 07 Aug 2024
Q1 2023 -$96.2K -$28.3K +$3.25K +10.3% 01 Jan 2023 31 Mar 2023 10-K 24 Jun 2024
Q4 2022 -$99.4K -$29.1K +$32.9K +53% 01 Oct 2022 31 Dec 2022 10-Q 05 Feb 2024
Q3 2022 -$132K -$21.5K -$431 -2.05% 01 Jul 2022 30 Sep 2022 10-Q 08 Nov 2023
Q2 2022 -$132K -$17.3K -$5.6K -47.9% 01 Apr 2022 30 Jun 2022 10-Q 14 Aug 2023
Q1 2022 -$126K -$31.5K -$24.4K -344% 01 Jan 2022 31 Mar 2022 10-K 09 Jun 2023
Q4 2021 -$102K -$62K -$47.7K -335% 01 Oct 2021 31 Dec 2021 10-Q 24 Jan 2023
Q3 2021 -$54.1K -$21.1K -$9.12K -76.2% 01 Jul 2021 30 Sep 2021 10-Q 07 Nov 2022
Q2 2021 -$45K -$11.7K -$1.59K -15.7% 01 Apr 2021 30 Jun 2021 10-Q 09 Aug 2022
Q1 2021 -$43.4K -$7.1K +$14.5K +67.2% 01 Jan 2021 31 Mar 2021 10-K 28 Jun 2022
Q4 2020 -$57.9K -$14.3K -$1.62K -12.9% 01 Oct 2020 31 Dec 2020 10-Q/A 03 Feb 2022
Q3 2020 -$56.3K -$12K -$335 -2.88% 01 Jul 2020 30 Sep 2020 10-Q 01 Nov 2021
Q2 2020 -$56K -$10.1K +$21K +67.5% 01 Apr 2020 30 Jun 2020 10-Q 12 Aug 2021
Q1 2020 -$77K -$21.6K -$5.58K -34.7% 01 Jan 2020 31 Mar 2020 10-K 23 Jun 2021
Q4 2019 -$71.4K -$12.6K +$39.7K +75.9% 01 Oct 2019 31 Dec 2019 10-Q 11 Feb 2021
Q3 2019 -$111K -$11.6K -$6.8K -141% 01 Jul 2019 30 Sep 2019 10-Q 10 Nov 2020
Q2 2019 -$104K -$31.1K -$12.6K -67.6% 01 Apr 2019 30 Jun 2019 10-Q 12 Aug 2020
Q1 2019 -$91.7K -$16.1K -$2.11K -15.1% 01 Jan 2019 31 Mar 2019 10-K/A 11 Aug 2020
Q4 2018 -$89.6K -$52.3K -$42K -410% 01 Oct 2018 31 Dec 2018 10-Q 10 Feb 2020
Q3 2018 -$47.6K -$4.82K +$3.32K +40.8% 01 Jul 2018 30 Sep 2018 10-Q 30 Oct 2019
Q2 2018 -$50.9K -$18.6K -$1.47K -8.57% 01 Apr 2018 30 Jun 2018 10-Q/A 29 Jul 2019
Q1 2018 -$49.5K -$14K -$5.81K -71.3% 01 Jan 2018 31 Mar 2018 10-K 24 Jun 2019
Q4 2017 -$43.6K -$10.3K -$8.04K -363% 01 Oct 2017 31 Dec 2017 10-Q 04 Feb 2019
Q3 2017 -$35.6K -$8.14K 01 Jul 2017 30 Sep 2017 10-Q 13 Nov 2018
Q2 2017 -$17.1K 01 Apr 2017 30 Jun 2017 10-Q 09 Aug 2018
Q1 2017 -$8.14K +$12.9K +61.2% 01 Jan 2017 31 Mar 2017 10-Q 07 Nov 2017
Q4 2016 -$2.21K 01 Oct 2016 31 Dec 2016 10-Q 08 Feb 2018
Q1 2016 -$21K 01 Jan 2016 31 Mar 2016 10-Q 07 Nov 2017
Q3 2011 -$16K +$1.8K +10.1% 01 Jun 2011 31 Aug 2011 10-Q 13 Oct 2011
Q3 2010 -$17.8K 01 Jun 2010 31 Aug 2010 10-Q 13 Oct 2011

REGENEREX PHARMA, INC. Annual Operating Income (Loss) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$1.83M +$1.64M +47.3% 01 Apr 2024 31 Mar 2025 10-K 30 Jun 2025
2023 -$3.47M -$3.37M -3504% 01 Apr 2023 31 Mar 2024 10-K 30 Jun 2025
2022 -$96.2K +$30.1K +23.8% 01 Apr 2022 31 Mar 2023 10-K 24 Jun 2024
2021 -$126K -$82.9K -191% 01 Apr 2021 31 Mar 2022 10-K 09 Jun 2023
2020 -$43.4K +$33.6K +43.6% 01 Apr 2020 31 Mar 2021 10-K 28 Jun 2022
2019 -$77K +$14.7K +16.1% 01 Apr 2019 31 Mar 2020 10-K 23 Jun 2021
2018 -$91.7K -$42.3K -85.5% 01 Apr 2018 31 Mar 2019 10-K/A 11 Aug 2020
2017 -$49.5K -$46.9K -1822% 01 Apr 2017 31 Mar 2018 10-K 24 Jun 2019
2016 -$2.57K 01 Apr 2016 31 Mar 2017 10-K 21 Jun 2018
* An asterisk sign (*) next to the value indicates that the value is likely invalid.